Double-Blind Comparison of Losartan, Lisinopril, and Metolazone in Elderly Hypertensive Patients with Previous Angiotensin-Converting Enzyme Inhibitor-Induced Cough-Reference-Cited by-同舟云学术

Double-Blind Comparison of Losartan, Lisinopril, and Metolazone in Elderly Hypertensive Patients with Previous Angiotensin-Converting Enzyme Inhibitor-Induced Cough

Published:1997-03 Issue:3 Volume:37 Page:253-257
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Chan Paul,Tomlinson Brian,Huang Tsuei-Yuen,Ko Jiing-Tang,Lin Tz-Shing,Lee Ying-Shiung

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference19 articles.

1. Converting enzyme inhibitors in the treatment of hypertension;Williams;N Engl J Med,1988

2. ACE inhibitors: a cornerstone for the treatment of heart failure;Braunwald;N Engl J Med,1991

3. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the CCS-1;Chinese Cardiac Study Collaborative Group;Lancet,1995

4. The incidence of cough during treatment with angiotensin converting enzyme inhibitors;Strocchi;J Hypertens Suppl,1989

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin‐converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta‐analysis;The Journal of Clinical Hypertension;2023-07-07

2. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase;Fundamental & Clinical Pharmacology;2017-09-05

3. Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials;The Journal of Clinical Psychiatry;2015-07-07

4. Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy;Aging and Heart Failure;2014

5. [Draft] Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drug and Biological Products;Biotechnology Law Report;2013-04